Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of “Hold” from Analysts

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have been assigned a consensus rating of “Hold” from the nineteen analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $29.2222.

A number of equities analysts have issued reports on TNDM shares. Morgan Stanley upped their target price on Tandem Diabetes Care from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Monday, March 2nd. TD Cowen started coverage on shares of Tandem Diabetes Care in a research report on Tuesday, January 27th. They set a “buy” rating and a $25.00 target price on the stock. Citigroup upped their price target on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Robert W. Baird set a $30.00 price objective on Tandem Diabetes Care and gave the company an “outperform” rating in a report on Tuesday, December 16th. Finally, Canaccord Genuity Group set a $35.00 target price on Tandem Diabetes Care and gave the stock a “buy” rating in a report on Wednesday, December 17th.

Tandem Diabetes Care Price Performance

Shares of NASDAQ:TNDM opened at $23.32 on Friday. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $29.65. The company has a debt-to-equity ratio of 2.00, a current ratio of 2.55 and a quick ratio of 2.02. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -7.60 and a beta of 1.63. The firm has a 50 day simple moving average of $21.71 and a 200 day simple moving average of $19.00.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its earnings results on Thursday, February 19th. The medical device company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.04. Tandem Diabetes Care had a negative net margin of 20.17% and a negative return on equity of 68.23%. The firm had revenue of $290.38 million for the quarter, compared to analysts’ expectations of $277.14 million. During the same quarter in the previous year, the firm posted $0.01 earnings per share. The company’s revenue was up 15.1% on a year-over-year basis. Research analysts predict that Tandem Diabetes Care will post -1.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tandem Diabetes Care

Institutional investors have recently modified their holdings of the company. Sector Gamma AS boosted its position in Tandem Diabetes Care by 28.0% during the third quarter. Sector Gamma AS now owns 269,542 shares of the medical device company’s stock valued at $3,272,000 after acquiring an additional 59,019 shares during the last quarter. Aberdeen Group plc lifted its stake in shares of Tandem Diabetes Care by 67.9% in the 3rd quarter. Aberdeen Group plc now owns 598,096 shares of the medical device company’s stock valued at $7,261,000 after purchasing an additional 241,878 shares during the period. Royce & Associates LP bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $6,191,000. Counterpoint Mutual Funds LLC bought a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at about $513,000. Finally, GSA Capital Partners LLP acquired a new stake in Tandem Diabetes Care during the third quarter worth approximately $1,201,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.